Articles related to CLINICAL COVID

According to new information revealed in a study of the AHA’s COVID-19 Cardiovascular Disease Registry, new onset AFib occurs in 5% of patients hospitalized with COVID-19. Patients who developed new-onset AFib experienced longer hospital stays and approximately 45% died during their hospitalization. Atrial fibrillation can directly increase the risk of stroke and prolong hospitalization. It is also an indirect marker of the insult that the heart is experiencing when patients are infected with COVID-19.

An observational analysis reviewed 54 studies and two medical record databases with data for 1.2 million individuals, to determine how many people experienced at least 1 of the 3 self-reported Long COVID symptom clusters 3 months after infection. The results indicate a Long COVID rate of 6.2%: 3.7% for ongoing respiratory problems, 3.2% for persistent fatigue with bodily pain or mood swings, and 2.2% for cognitive problems.

Neurologic complications of COVID are leading to an increase in demand for both acute and long-term neurologic evaluation and management. Doctors Koralnik, Liotta, and Graham have been investigating the pathogenic mechanisms of acute and long-term COVID-19 and discuss here their guideline on managing neurologic complications of COVID.

This cohort study discovered that depression, anxiety, perceived stress, loneliness, and worry about COVID-19 were prospectively associated with a 1.3- to 1.5-fold increased risk of self-reported post-COVID-19 conditions, as well as an increased risk of daily life impairment related to post-COVID-19 conditions.

To assess short-term risk for severe cardiovascular events (excluding myocarditis and pericarditis) after COVID-19 vaccination, adults younger than 75 years hospitalized for PE, acute MI, hemorrhagic stroke, or ischemic stroke (73,325 events) were reviewed in relation to a 1st or 2nd COVID vaccine dose. No association was found between the Pfizer–BioNTech or Moderna vaccine and severe cardiovascular events. The first dose of the Oxford–AstraZeneca vaccine was associated with acute MI and PE in the second week after vaccination. An association with MI in the second week after a single dose of the Janssen vaccine could not be ruled out.